Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4968406 | 1.00 | MAPT (0.56) | MAPTRAB9AKMT2AHDAC1LMNA | |
| SCHEMBL14523935 | 0.88 | MAPT (0.53) | MAPTRAB9AKMT2AHDAC1LMNA | |
| SCHEMBL6713011 | 0.83 | MCHR1 (0.54) | MAPTKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL28183332 | 0.82 | HCAR3 (0.65) | MAPTKMT2AHDAC1ALDH1A1MEN1 | |
| SCHEMBL6712490 | 0.81 | MAPT (0.51) | MAPTRAB9AKMT2AHDAC1LMNA | |
| SCHEMBL4968452 | 0.81 | TERT (0.47) | MAPTKMT2AALDH1A1MAPK1MEN1 | |
| SCHEMBL6232184 | 0.79 | MAPT (0.68) | MAPTRAB9AHDAC1LMNAALDH1A1 | |
| SCHEMBL5443785 | 0.79 | MAPT (0.48) | MAPTRAB9AKMT2AHDAC1ALDH1A1 | |
| SCHEMBL5443793 | 0.79 | MAPT (0.48) | MAPTRAB9AKMT2AHDAC1ALDH1A1 | |
| SCHEMBL2326316 | 0.78 | PKM (0.61) | MAPTRAB9AHDAC1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670770-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | disclosed |
| EP-1673369-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030761-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | F12, H1-3, H1-4 | MAPT 4445/4885RAB9A 2415/4885KMT2A 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.